Acquired Peripheral Neuropathy

Introduction

Acquired peripheral neuropathy refers to damage to the peripheral nervous system that develops after birth, rather than being inherited. This condition affects the nerves outside of the brain and spinal cord, impacting sensation, movement, and organ function. Peripheral neuropathy can manifest in various forms, often beginning with sensory deficits such as paresthesia (tingling or prickling sensation) and pain, typically in a “glove and stocking” distribution, affecting the hands and feet first due to damage to longer neurons.^[1]

Biological Basis

The biological basis of acquired peripheral neuropathy involves damage to nerve fibers, which can be caused by a multitude of factors, including metabolic disorders, exposure to toxins, infections, autoimmune diseases, and certain medications. While diverse etiologies exist, genetic factors are increasingly recognized as playing a significant role in an individual’s susceptibility and the severity of acquired peripheral neuropathy. For instance, genome-wide association studies (GWAS) have identified specific genetic variants associated with increased risk. In patients receiving D-drug-containing regimens, polymorphisms withinIL2RA (rs12722486 ), ZNF648 (rs7554128 ), and near RSP04 (rs502716 ) have been linked to peripheral neuropathy.^[2]Similarly, taxane-induced peripheral neuropathy has been associated with variants such asrs910920 in NXN ^[3]and docetaxel-induced neuropathy has been linked to polymorphisms inVAC14. ^[4]In the context of chemotherapy-induced peripheral neuropathy (CIPN), rare coding variants inGPR68 have been identified. ^[1]For diabetic peripheral neuropathy (DPN), genetic loci such as one on chromosome 2q24, which may influenceSCN2A expression, have been found to predict risk. ^[5]These genetic predispositions can influence nerve repair mechanisms, drug metabolism, or immune responses, thereby modulating the development and progression of neuropathy.

Clinical Relevance

Acquired peripheral neuropathy is clinically relevant due to its widespread impact on patient quality of life and significant healthcare burden. Symptoms can range from mild numbness and tingling to severe pain, muscle weakness, and autonomic dysfunction, affecting daily activities and leading to disability. Early diagnosis and management are crucial to prevent progression and alleviate symptoms. Diagnostic criteria, such as a Michigan Neuropathy Screening Instrument (MNSI) clinical examination score greater than 2.0, are used to identify diabetic peripheral neuropathy, demonstrating high sensitivity and specificity.^[5]Despite decades of research, preventing or effectively treating many forms of acquired peripheral neuropathy, particularly chemotherapy-induced neuropathy, remains challenging.^[1] Understanding the underlying genetic factors can pave the way for personalized medicine approaches, enabling risk stratification, targeted prevention strategies, and the development of novel therapies.

Social Importance

The social importance of acquired peripheral neuropathy stems from its prevalence and profound impact on individuals and society. Conditions like diabetic peripheral neuropathy affect millions globally, leading to complications such as foot ulcers and amputations, which incur substantial healthcare costs and reduce productivity. Chemotherapy-induced peripheral neuropathy can force patients to reduce or discontinue life-saving cancer treatments, significantly affecting prognosis and quality of life. The chronic pain and functional limitations associated with neuropathy can lead to isolation, depression, and reduced participation in social and economic activities. Research into the genetic underpinnings of acquired peripheral neuropathy is vital for identifying at-risk populations, developing preventative measures, and improving therapeutic outcomes, ultimately enhancing the well-being and autonomy of affected individuals and reducing the societal burden of this debilitating condition.

Limitations

Methodological and Statistical Constraints

Genetic research on acquired peripheral neuropathy faces several methodological and statistical limitations that impact the interpretation and generalizability of findings. The sample sizes across studies vary significantly, from 254 patients in some analyses^[2] to thousands in others ^[1]which can limit the statistical power to detect genetic variants with small effect sizes or those that are less common. This variability also complicates meta-analyses and replication efforts, as inconsistencies in cohort size can lead to conflicting results or an inability to confirm initial associations. Furthermore, replication gaps are a noted issue, with some studies observing a substantial number of reported alleles failing to replicate, often attributed to factors like low allele frequency or potential effect-size inflation.^[6]

While power calculations are often performed to ensure sufficient statistical power to detect specific genetic effects ^[3] these are based on predefined assumptions about allele frequencies and effect sizes, which may not always reflect the true genetic landscape, especially for novel or rare variants. The use of various statistical models, including logistic regression, Cox models, and linear mixed models ^[7] along with imputation methods ^[7] introduces complexity. Although genomic inflation factors are estimated to mitigate population stratification ^[3] residual biases can still distort p-values and potentially lead to false-positive associations in genome-wide analyses.

Phenotypic Heterogeneity and Population Bias

A significant limitation in studying acquired peripheral neuropathy is the heterogeneity in its phenotypic definition and measurement across different studies. The grading of neuropathy often varies, with some studies analyzing different severity thresholds (e.g., grade ≥1, ≥2, or 3)^[2] while others focus on specific diagnostic criteria such as a clinical examination score ^[5]or Medical Research Council (MRC) standards for muscle strength.^[8]This lack of a standardized assessment protocol hinders direct comparisons and meta-analyses, potentially obscuring consistent genetic signals or introducing noise due to differing diagnostic sensitivities and specificities. Moreover, the classification of controls in some datasets might include individuals at pre-disease stages^[9] which could dilute true genetic associations by miscategorizing early-stage cases.

Another critical limitation is the predominant focus on populations of European ancestry in many genetic studies ^[7] with other research concentrating on specific groups such as Japanese ^[6] or Hispanic/Latino populations. ^[10]This creates a substantial bias in generalizability, as genetic architectures, including allele frequencies and linkage disequilibrium patterns, can differ significantly across diverse ancestries. Findings from one population may not be directly transferable or hold the same effect size in another, limiting the global applicability of identified genetic risk factors. While some studies attempt meta-analyses across different racial or ethnic groups^[2] the potential for population stratification bias remains a concern, necessitating careful adjustment to avoid spurious associations. ^[7]

Complex Etiology and Remaining Knowledge Gaps

Acquired peripheral neuropathy is a complex condition influenced by a myriad of genetic and environmental factors, and existing research often provides only a partial view of its intricate etiology. While genetic studies identify specificSNPs associated with risk, they frequently do not fully capture the complex interplay of environmental exposures and gene-environment interactions. For instance, residential exposure to traffic has been shown to modify genetic associations in other related conditions ^[11]indicating that such unmeasured environmental confounders could significantly influence neuropathy risk and mask underlying genetic pathways. The limited consideration of these external factors in primarily gene-focused studies restricts a comprehensive understanding of how genetic susceptibility is modulated by the environment.

Furthermore, challenges in accurately estimating heritability ^[6] coupled with the frequent focus on common genetic variants ^[1]suggest the presence of “missing heritability” for acquired peripheral neuropathy. This implies that a substantial portion of the genetic variance remains unexplained by currently identified commonSNPs, potentially due to the overlooked contributions of rare coding variants ^[1]structural variations, or more complex genetic architectures. The current body of literature on the genetic underpinnings of acquired peripheral neuropathy is still considered nascent^[5] highlighting that many genetic and biological pathways involved in its development and progression are yet to be discovered. This ongoing knowledge gap necessitates further investigation with larger, more diverse cohorts and the application of advanced sequencing technologies to uncover the full genetic landscape.

Variants

Genetic variations play a crucial role in an individual’s susceptibility to acquired peripheral neuropathy, influencing diverse biological pathways from immune responses to metabolic regulation and neuronal integrity. Among these, an intronic polymorphism within theIL2RA gene, rs12722486 , has shown a strong association with severe forms of peripheral neuropathy. TheIL2RAgene encodes a subunit of the receptor for interleukin-2, a cytokine vital for immune system regulation, particularly in the development and function of T cells.^[12]Variants in this gene can alter immune responses, which may contribute to inflammatory or autoimmune-mediated nerve damage, thereby increasing the risk for grade 3 peripheral neuropathy, especially in populations such as White patients.^[2]

Other variants impact genes central to metabolic health and cellular function, which are foundational to maintaining nerve integrity. Polymorphisms in PHGDH (rs477992 , rs662602 , rs562038 ), ATP7B (rs185185149 ), and GCKR (rs1260326 ) are relevant due to their roles in critical metabolic processes. PHGDHis essential for serine biosynthesis, a pathway that provides building blocks for lipids important in myelin formation and neurotransmitter synthesis, directly impacting neuronal health.ATP7B is involved in copper transport, and maintaining proper copper levels is vital for numerous enzymatic functions in the nervous system, with imbalances leading to neurodegenerative conditions. GCKRregulates glucokinase activity, a key enzyme in glucose metabolism; dysregulation here can contribute to conditions like diabetes, a leading cause of acquired peripheral neuropathy.^[5] Variations in these genes can disrupt metabolic homeostasis, leading to oxidative stress, energy deficits, or altered structural components, all of which can predispose individuals to peripheral nerve damage.

Further genetic influences on peripheral neuropathy involve genes governing mitochondrial function, extracellular matrix integrity, and gene expression regulation. Variantsrs12464737 and rs12615158 associated with PNPT1 and EFEMP1 respectively, point to mitochondrial health and structural support as crucial factors. PNPT1 is involved in mitochondrial RNA processing, essential for the organelle’s energy production, while EFEMP1 contributes to the extracellular matrix, which provides structural support and signaling cues for nerves. The long non-coding RNA CDKN2B-AS1, with variants like rs6475604 and rs944801 , influences cell cycle regulation and has been linked to peripheral vascular disease^[9] a condition that can compromise nerve blood supply. Similarly, SNRPC (rs75398113 ) is critical for mRNA splicing, ensuring proper protein synthesis for nerve maintenance. The UCA1-AS1 - CYP4F36P region (rs12611275 ), LINC02881 - CXCL12 (rs266095 ), and SCN7A - XIRP2 (rs13417783 ) involve regulatory RNAs, chemokines, and ion channels, respectively. CXCL12 plays a role in nerve regeneration and inflammatory responses, while SCN7A contributes to the electrical excitability of neurons, and XIRP2 is involved in cytoskeletal organization, all of which are fundamental to nerve function and repair following injury.

Key Variants

RS ID	Gene	Related Traits
rs12464737 rs12615158	PNPT1 - EFEMP1	Inguinal hernia optic neuritis, neuropathy
rs477992 rs662602 rs562038	PHGDH	metabolite measurement serine measurement hematocrit total cholesterol measurement red blood cell density
rs185185149	ATP7B	optic neuritis, neuropathy
rs6475604 rs944801	CDKN2B-AS1	open-angle glaucoma colorectal cancer Antiglaucoma preparations and miotics use measurement glaucoma optic neuritis, neuropathy
rs75398113	SNRPC	low density lipoprotein cholesterol measurement, lipid measurement cholesterol:totallipids ratio, low density lipoprotein cholesterol measurement free cholesterol measurement, low density lipoprotein cholesterol measurement esterified cholesterol measurement obese body mass index status
rs12611275	UCA1-AS1 - CYP4F36P	metabolite measurement gamma-CEHC glucuronide measurement gamma-CEHC measurement urinary metabolite measurement protein measurement
rs12722486	IL2RA	response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy
rs1260326	GCKR	urate measurement total blood protein measurement serum albumin amount coronary artery calcification lipid measurement
rs266095	LINC02881 - CXCL12	response to reverse transcriptase inhibitor, HIV-1 infection, peripheral neuropathy
rs13417783	SCN7A - XIRP2	peripheral neuropathy

Signs and Symptoms

Clinical Presentation and Severity Grading

Acquired peripheral neuropathy presents with a diverse range of clinical manifestations, primarily affecting sensory and motor functions. Common symptoms include numbness, tingling sensations, and pain, often accompanied by motor weakness.^[13]These symptoms typically follow a distal, symmetrical pattern, frequently described as “stocking-glove” distribution. Various underlying conditions can lead to acquired peripheral neuropathy, such as exposure to microtubule inhibitor chemotherapy agents like vincristine and taxanes, which can induce peripheral neurotoxicity^{[3], [7], [14]}. ^[4]Type 2 diabetes is another significant cause, leading to diabetic neuropathy.^[5]

The severity of acquired peripheral neuropathy can vary considerably among individuals and is often graded to assess its impact and progression. For instance, vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia is categorized into grades, ranging from None to Grade 1 for milder cases, to Grade 2 or higher for more severe episodes, indicating its dose-limiting toxicity.^[14] Such grading systems are crucial for monitoring treatment toxicities and informing clinical management, particularly for conditions that compromise quality of life. ^[14]

Assessment Modalities and Measurement Approaches

The assessment of acquired peripheral neuropathy involves both subjective and objective measures. Patient-reported outcomes capture the individual’s direct experience of symptoms like numbness, tingling, and pain, providing valuable subjective insights into the neuropathy’s impact.^[15] Complementary to this are clinician-reported assessments, which rely on neurological examinations and diagnostic tools to objectively evaluate sensory and motor deficits. ^[15]For chronic and progressive diseases, detailed physician-documented electronic medical records (EMRs) and longitudinal follow-up are critical for refining diagnosis and tracking disease progression over time, enhancing data accuracy compared to reliance on self-reported data which can be subject to recall bias.^[16]

Beyond clinical examination, advanced measurement approaches can offer deeper insights into the underlying pathology. At a cellular level, neurite changes, such as relative total neurite outgrowth, number of processes, branching, and process length, can be determined through individual cell measurements. ^[4]These objective cellular assays provide quantifiable data on neuronal damage or dysfunction, which can be crucial for understanding the mechanistic basis of neuropathy, especially in cases induced by agents like docetaxel.^[4]Such detailed measurements contribute to a comprehensive understanding of the neuropathy’s presentation and progression.

Variability, Heterogeneity, and Diagnostic Significance

Acquired peripheral neuropathy exhibits significant variability and heterogeneity in its presentation, influenced by factors such as age, genetic background, and the specific etiology. For example, vincristine-related neuropathy in children with acute lymphoblastic leukemia shows variation in occurrence and severity, with age at diagnosis and genetically-determined ancestry being relevant characteristics.^[14] Similarly, the age distribution of affected populations can vary, with significant proportions of participants in some cohorts being under 45 years of age. ^[16] This phenotypic diversity necessitates careful consideration during diagnosis and management.

Understanding the varied presentations and underlying factors holds significant diagnostic and prognostic value. Genetic factors, such as specific loci, can predict an individual’s risk for developing peripheral neuropathy, as seen with a locus on chromosome 2q24 predicting risk in Type 2 Diabetes.^[5]Similarly, genetic germline variants can be associated with the occurrence or severity of vincristine-related neuropathy.^[14]However, predicting the onset of conditions like taxane-induced peripheral neuropathy remains challenging.^[3] Recognizing these correlations is vital for identifying individuals at higher risk, informing differential diagnosis, and guiding personalized management strategies to mitigate treatment toxicities and improve quality of life. ^[17]

Causes of Acquired Peripheral Neuropathy

Acquired peripheral neuropathy is a complex condition influenced by a combination of genetic predispositions, environmental exposures, and an individual’s overall health status. Unlike inherited forms, acquired neuropathy develops during a person’s lifetime due to various external and internal factors that damage the peripheral nerves.

Genetic Susceptibility and Polygenic Influences

Acquired peripheral neuropathy often has a polygenic basis, meaning that multiple genetic variants collectively contribute to an individual’s risk and response to environmental triggers.^[9]While no single polymorphism has been consistently identified at genome-wide significance for certain types of acquired neuropathy, specific gene candidates, such asKIF1A, LITAF, and NEFL, have been implicated in modulating an individual’s susceptibility to conditions like D-drug-associated peripheral neuropathy.^[2] These genetic factors can influence critical biological processes, including nerve repair mechanisms, axonal transport, and the regulation of inflammatory responses, thereby impacting an individual’s vulnerability to nerve damage.

Beyond the effects of individual genes, non-additive genetic associations, often referred to as gene-gene interactions, play a significant role in the genetic architecture of complex, age-related conditions like neuropathy.^[9]These interactions occur when the combined effect of multiple genes on disease risk is greater than the sum of their individual contributions. Furthermore, genetic loci associated with related peripheral health issues, such as theATXN2-SH2B3locus linked to peripheral arterial disease, suggest a broader genetic landscape that can impact peripheral health, potentially through shared pathways that affect both vascular and nerve integrity.^[18]

Environmental Exposures and Medication Effects

A primary environmental cause of acquired peripheral neuropathy is exposure to certain medications, particularly those used in the treatment of other serious illnesses. For example, D-drug-containing regimens, specifically ddI/d4T, which are part of HIV treatment protocols, are well-documented culprits in inducing distal sensory peripheral neuropathy.^[2]These pharmacological agents exert direct neurotoxic effects, leading to nerve damage and the manifestation of neuropathy symptoms in patients receiving these therapies. The emergence of neuropathy as a side effect highlights the direct causal link between specific medical treatments and nerve injury.

Beyond pharmaceutical agents, broader environmental exposures can also contribute to the development of peripheral neuropathy. While specific direct links to neuropathy for all environmental factors are not extensively detailed in some studies, research on related peripheral conditions indicates that factors like residential exposure to traffic can interact with genetic predispositions to influence peripheral arterial disease.^[11]This suggests that various external environmental agents, including pollutants or toxins, may act as stressors on the peripheral nervous system, potentially contributing to neuropathy onset or exacerbation, especially in genetically susceptible individuals.

Gene-Environment Interplay and Disease Modifiers

Acquired peripheral neuropathy frequently arises from a dynamic interplay between an individual’s genetic makeup and their exposure to environmental factors. Genetic predisposition can profoundly modify how an individual responds to environmental triggers, influencing both the likelihood of developing neuropathy and its eventual severity. For instance, specific genetic polymorphisms, including those found inKIF1A, LITAF, and NEFL, have been identified as potential modifiers of susceptibility to peripheral neuropathy in HIV-infected patients exposed to D-drug regimens.^[2] These findings underscore how inherent genetic variations can render some individuals more vulnerable to the neurotoxic effects of medications.

This critical concept of gene-environment interaction extends beyond drug-induced neuropathy to encompass other environmental influences. Studies have shown that genetic variants within gene families, such as theBMPgene family, can modify the association between residential exposure to traffic and the risk of conditions like peripheral arterial disease.^[11] This demonstrates a general principle where an individual’s genetic background dictates their physiological response to external stressors, such as environmental pollutants, thereby either intensifying or mitigating their detrimental impact on the health of the peripheral nervous system. Such interactions are fundamental to understanding the personalized risk profiles for complex diseases.

Comorbidities and Age-Related Contributions

The presence of co-occurring medical conditions, or comorbidities, significantly influences the development and progression of acquired peripheral neuropathy. Diseases that necessitate specific drug regimens, such as HIV infection treated with D-drugs, can directly lead to neuropathy as an adverse effect of the essential therapy.^[2]Beyond direct drug-induced damage, other health issues, particularly those that compromise vascular health, like peripheral arterial disease (which itself has identified genetic associations^[18]), can indirectly contribute to neuropathy by impairing blood flow and nutrient supply to peripheral nerves, leading to ischemic damage and dysfunction.

Age is a fundamental and pervasive factor contributing to the incidence of many complex diseases, including acquired peripheral neuropathy. The natural aging process involves a gradual accumulation of cellular damage and a decline in the regenerative capacity of peripheral nerves, making older individuals inherently more susceptible to developing neuropathy from various causes. Research indicates that non-additive genetic associations, reflecting complex gene interactions, play a role in the manifestation of age-related complex diseases, suggesting that the genetic underpinnings of neuropathy risk may become more pronounced and influential as individuals age.^[9]This cumulative effect of genetic predisposition, environmental exposures, and age-related physiological changes collectively increases the lifetime risk of acquired peripheral neuropathy.

Biological Background of Acquired Peripheral Neuropathy

Acquired peripheral neuropathy refers to damage to the peripheral nerves, which are the nerves outside of the brain and spinal cord. This condition can arise from various factors, including chemotherapy, diabetes, infections, or toxins, leading to symptoms such as pain, numbness, tingling, and weakness. Understanding the underlying biological mechanisms is crucial for developing effective prevention and treatment strategies.

Cellular and Molecular Mechanisms of Nerve Damage

Acquired peripheral neuropathy frequently involves the degeneration of axons, particularly those of longer sensory neurons, resulting in characteristic “glove and stocking” patterns of sensory deficits.^[1] Maintaining healthy neuronal function depends on several intricate cellular processes, including proper lysosomal activity and phosphoinositide metabolism. For example, the VAC14 gene is critical for the production of PI^{[19], [20]}P2, a lipid vital for lysosomal function, and specific polymorphisms in VAC14have been linked to an increased risk of docetaxel-induced neuropathy.^[4] Disruptions in this pathway, such as those caused by mutations in FIG4, which also affects PI^{[19], [20]}P2 synthesis, can lead to impaired lysosomal function and severe neuropathies. ^[4]

The electrical signaling fundamental to nerve function relies heavily on various ion channels. Voltage-gated sodium channels, in particular, are essential for the initiation and propagation of action potentials along nerve fibers. While rare mutations inSCN2Aare associated with neurodevelopmental disorders, specific sodium channels likeNaV1.3 and NaV1.7, encoded by SCN3A and SCN9Arespectively, have established roles in the development of diabetic peripheral neuropathy.^[5] Their dysfunction can contribute to axonal degeneration. ^[21] Additionally, G protein-coupled receptors (GPCRs) play a significant role; for instance, GPR68, a proton-sensing GPCR found in nociceptors of the dorsal root ganglion (DRG), has rare coding variants associated with chemotherapy-induced peripheral neuropathy (CIPN).^[22] The precise phosphorylation patterns of GPCRs are also crucial for orchestrating downstream signaling events, including those mediated by arrestins. ^[23]

Sphingolipid metabolism represents another key molecular pathway involved in neuropathic pain. Research indicates that the activation of sphingosine-1-phosphate receptor subtype 1 (S1PR1) is a prerequisite for the development and maintenance of paclitaxel-induced neuropathic pain.^[7] The dysregulation of sphingolipid metabolism, involving both S1PR1 and S1P3receptors, contributes to neuropathic pain induced by various chemotherapeutic agents.^[7] Specifically, the S1P3 receptor can initiate neuronal retraction by activating the RhoA/ROCK pathway, a process linked to CRMP2 phosphorylation. ^[24]These sphingosine 1-phosphate receptors are expressed in the dorsal root ganglia and sensory neurons, highlighting their direct involvement in pain signaling pathways.^[7]

Genetic Predisposition and Regulatory Networks

An individual’s genetic makeup significantly influences their susceptibility to acquired peripheral neuropathy, with numerous genome-wide association studies (GWAS) identifying specific genetic variants linked to conditions such as CIPN and diabetic peripheral neuropathy.^[4] For instance, polymorphisms within the VAC14gene have been mechanistically validated to increase the risk of docetaxel-induced neuropathy.^[4] Similarly, rare coding variants in the GPR68 gene have shown associations with CIPN across multiple clinical trials. ^[1]Beyond coding regions, GWAS have also pointed to the involvement of intergenic single nucleotide polymorphisms (SNPs), such asrs11017056 and rs11840337 , suggesting that regulatory elements outside of genes can also modulate neuropathy risk.^[4]

Other genes are also implicated in nerve health and neuropathy risk.FGD4, which encodes the Rho GDP/GTP exchange factor FRABIN, is associated with Charcot-Marie-Tooth type 4H, a severe hereditary neuropathy.^[7]While Charcot-Marie-Tooth disease is hereditary, the function ofFGD4 in maintaining nerve structure and signaling pathways underscores its general relevance to nerve integrity. Genotypes of CYP2C8have been associated with peripheral neuropathy or the need for early dose reduction in patients treated with paclitaxel.^[7]For diabetic neuropathy, a specific genetic locus on chromosome 2q24 has been identified as a predictor of risk in type 2 diabetes, indicating how particular genomic regions can influence neuropathy development in chronic metabolic diseases.^[5] Furthermore, MAPK14has been associated with diabetic foot ulcers, suggesting its role in the broader spectrum of diabetic complications, including neuropathy.^[25] Mutations in NEFL, which encodes the neurofilament light chain, are known to cause severe forms of Charcot-Marie-Tooth disease, highlighting the critical importance of cytoskeletal components for normal nerve function.^[26]

Pathophysiological Processes and Inflammatory Responses

The pathophysiology of acquired peripheral neuropathy involves a complex interplay of direct nerve injury and subsequent inflammatory and immune responses. In conditions like chemotherapy-induced peripheral neuropathy (CIPN), therapeutic agents directly damage peripheral nerves, leading to sensory deficits and pain.^[1] This initial insult can provoke reactive processes in surrounding cells and tissues. For instance, CX3CL1-mediated macrophage activation has been shown to contribute to neuronal apoptosis in the dorsal root ganglion (DRG) and the progression of painful peripheral neuropathy, particularly with paclitaxel treatment.^[7]These activated macrophages release various inflammatory mediators that can exacerbate nerve damage and intensify pain signaling.

Beyond macrophages, other glial cells contribute significantly to the neuropathic process. Satellite glial cells, which encapsulate DRG neurons, undergo changes in their transcriptional profiles following peripheral nerve injury. ^[27]These changes suggest a dynamic cellular response that can influence neuronal function and recovery. In diabetic neuropathy, persistent mechanical allodynia, a common and debilitating symptom, is positively correlated with an increase in activated microglia and elevated P-p38 mitogen-activated protein kinase activation. ^[28]Microglial activation within the central nervous system, particularly in the dorsal horn, contributes to central sensitization, a phenomenon where the nervous system becomes hypersensitive to pain.^[7]This central sensitization can be modulated by biomolecules like sphingosine-1-phosphate and its receptors, with agents such as Fingolimod demonstrating the ability to reduce neuropathic pain behaviors throughS1PR1-dependent inhibition of central sensitization. ^[7]

Systemic and Tissue-Level Manifestations

Acquired peripheral neuropathy predominantly impacts the peripheral nervous system, particularly the longer sensory neurons, leading to characteristic symptoms such as sensory deficits and paresthesia, often manifesting in a “glove and stocking” distribution that starts in the hands and feet.^[1]The dorsal root ganglia (DRG) are central to the development of neuropathic pain, as they house the cell bodies of sensory neurons. Within these ganglia, crucial biomolecules like G protein-coupled receptors (GPR68) and sphingosine 1-phosphate receptors (S1PR1, S1P3) are expressed, mediating pain signals and neuronal responses to injury.^[7]Damage within the DRG can result in neuronal apoptosis, which contributes to the overall loss of nerve function and the progression of neuropathy.^[7]

The repercussions of peripheral nerve damage extend beyond local effects, often leading to systemic consequences and chronic pain states. Painful sensations and allodynia, defined as pain caused by normally non-painful stimuli, are common manifestations of acquired neuropathy.^[1]This heightened pain sensitivity can involve not only the peripheral nerves but also the central nervous system, particularly through the process of central sensitization in the dorsal horn.^[7]Conditions like diabetic neuropathy exemplify the systemic nature of the disease, where metabolic disruptions inherent to diabetes lead to widespread nerve damage throughout the body.^[25]The severity of neuropathy can be a dose-limiting factor for treatments, such as chemotherapy, underscoring its significant impact on patient quality of life and the administration of therapeutic regimens.^[1]

Pathways and Mechanisms

Receptor-Mediated Signaling and Intracellular Cascades

Acquired peripheral neuropathy often involves dysregulation of crucial neuronal signaling pathways, initiated by various receptor activations that culminate in altered cellular responses. For instance, rare coding variants inGPR68, a G protein-coupled receptor (GPCR), have been associated with chemotherapy-induced peripheral neuropathy (CIPN).^[1] GPCRs, including proton-sensing GPCRs found on dorsal root ganglion (DRG) nociceptors, orchestrate signaling through phosphorylation patterns that dictate arrestin-mediated responses and subsequent intracellular cascades. ^[22]The sphingosine-1-phosphate receptor subtype 1 (S1PR1) also plays a significant role, with its activation being essential for the development of paclitaxel-induced neuropathic pain, and genetic variations inS1PR1have been validated in microtubule targeting agent-induced sensory peripheral neuropathy.^[7] Activation of S1P3, another sphingosine-1-phosphate receptor, can initiate neuronal retraction by activating RhoA/ROCK signaling, which is linked to CRMP2 phosphorylation and subsequent cytoskeletal changes.^[24]

Further downstream, intracellular signaling pathways like the p38 mitogen-activated protein kinase (MAPK) pathway are implicated in neuropathy progression. Increased activation of P-p38 MAPK in activated microglia is correlated with persistent mechanical allodynia in diabetic neuropathy models, suggesting a role in pain sensitization.^[28] This activation can be triggered by reactive oxygen species and interacts with other pathways, such as NF-κB and TGF-β signaling, leading to a complex network of responses that influence neuronal damage and inflammation. ^[20] Additionally, CX3CL1-mediated macrophage activation contributes to DRG neuronal apoptosis and painful peripheral neuropathy, highlighting the interplay between immune signaling and neuronal integrity.^[22]The precise regulation of voltage-gated sodium channels, vital for neuronal excitability, is also critical, with the mammalian silencer proteinREST restricting their expression to neurons. ^[29]

Metabolic Dysregulation and Axonal Energetics

Metabolic pathways are profoundly affected in acquired peripheral neuropathy, particularly concerning energy production and lipid metabolism, which are vital for maintaining axonal health. Mitochondrial dysfunction, characterized by DNA depletion and oxidative stress, is a key mechanism of cellular damage, particularly in neuropathies induced by nucleoside reverse transcriptase inhibitors.^[30]This impairment in energy metabolism directly impacts axonal function and contributes to degeneration, often in conjunction with altered sodium channel activity.^[21]The dysregulation of sphingolipid metabolism represents another critical metabolic pathway contributing to neuropathy, with specific implications for bortezomib-induced neuropathic pain.^[31]

Furthermore, a polymorphism in VAC14has been mechanistically validated to increase the risk of docetaxel-induced neuropathy.^[4] VAC14 is integral to the regulation of PI^{[19], [20]}P2 levels, and its deficiency leads to impaired lysosome function, impacting cellular catabolism and membrane dynamics. ^[32]This suggests that defects in lysosomal trafficking and phospholipid metabolism contribute to the pathogenesis of certain acquired neuropathies, mirroring mechanisms seen in some inherited neuropathies like Charcot-Marie-Tooth disease type 4J, which involvesFIG4 mutations also affecting PI^{[19], [20]}P2 metabolism. ^[32]These metabolic imbalances disrupt the intricate cellular environment required for neuronal maintenance and repair, leading to progressive neuropathy.

Cytoskeletal Dynamics and Axonal Transport

The maintenance of axonal integrity and efficient intracellular transport relies heavily on the dynamic regulation of the cytoskeleton, particularly microtubules and their associated motor proteins. The intricate relationship between microtubules and these motor proteins is fundamental for proper axon growth and maintenance. ^[33] Disruptions in this system are directly implicated in peripheral neuropathies, as evidenced by KIF1A missense mutations, which cause autosomal recessive spastic paraplegia and lead to distinct phenotypes based on the nature of the mutation. ^[34] KIF1A is a kinesin motor protein responsible for anterograde transport of vesicles and organelles along microtubules, and its dysfunction impairs the delivery of essential components to distal axons.

Another crucial component in cytoskeletal regulation is FGD4, which encodes the Rho GDP/GTP exchange factor FRABIN. Mutations in FGD4 are known to cause autosomal recessive Charcot-Marie-Tooth type 4H, highlighting its role in cytoskeletal organization. ^[35] Variants in FGD4have also been associated with peripheral neuropathy risk in paclitaxel-treated patients, suggesting that dysregulation of Rho GTPase signaling, which controls actin dynamics and cell morphology, contributes to acquired forms of neuropathy.^[36]These mechanisms underscore how disturbances in the structural and transport machinery of neurons directly contribute to axonal degeneration and the clinical manifestations of peripheral neuropathy.

Transcriptional and Post-Translational Regulatory Mechanisms

Gene regulation and protein modification represent critical control points in the development and progression of acquired peripheral neuropathy, influencing neuronal resilience and repair. The transcriptional fingerprint of satellite glial cells undergoes significant changes following peripheral nerve injury, indicating a dynamic regulatory response in non-neuronal cells supporting peripheral nerves.^[27]This highlights the importance of glial-neuronal interactions and the coordinated gene expression changes in both cell types. Furthermore, regulatory mechanisms extend to noncoding RNAs, such as long noncoding RNAs, which play roles in genome regulation and are implicated in diabetes vascular complications, potentially influencing diabetic neuropathy.^[37]

Protein modifications, particularly phosphorylation, are central to post-translational regulation and pathway activity. For instance, the phosphorylation patterns of GPCRs are crucial for their signaling and interaction with arrestins, influencing downstream cellular responses. ^[23] The phosphorylation of CRMP2, mediated by RhoA/ROCK signaling, also plays a role in neuronal retraction, demonstrating how specific protein modifications can alter neuronal structure and function. ^[24] Beyond phosphorylation, other regulatory mechanisms include the activity of histone deacetylases, such as HDAC9, which influences gene expression by targeting microRNA clusters, potentially impacting processes like angiogenesis that are relevant to peripheral nerve health. ^[38]These integrated regulatory layers determine the cellular response to injurious stimuli and the capacity for recovery or degeneration in peripheral neuropathy.

Clinical Relevance

Acquired peripheral neuropathy, a common neurological condition, carries significant clinical relevance due to its impact on patient quality of life, healthcare burden, and the potential for personalized therapeutic approaches. Genetic research, particularly genome-wide association studies (GWAS), has begun to elucidate the underlying genetic predispositions and modifiers that influence its development, severity, and response to treatment. This growing understanding is crucial for advancing diagnostic, prognostic, and preventative strategies in clinical practice.

Risk Stratification and Early Identification

Genetic insights offer a powerful tool for identifying individuals at higher risk of developing acquired peripheral neuropathy, facilitating proactive intervention and personalized surveillance. For instance, specific genetic variants, such as theCEP72TT genotype, have been linked to a significantly increased cumulative incidence of vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia, reaching over 60% compared to other genotypes.^[14]Similarly, a genetic locus on chromosome 2q24 has been identified as a predictor of peripheral neuropathy risk in type 2 diabetes, highlighting a genetic predisposition to diabetic peripheral neuropathy (DPN).^[5] Utilizing polygenic risk scores (PRS), which integrate multiple genetic variants, alongside clinical features like age and sex, can enhance the accuracy of risk prediction for various diseases, although PRS models alone typically show modest predictive value (AUC ~0.6), their combination with clinical data significantly improves predictive capability. ^[16] This allows for targeted prevention strategies and earlier diagnostic workups in high-risk patient populations, potentially mitigating severe outcomes.

Prognostic Indicators and Treatment Optimization

Genetic markers also provide valuable prognostic information, predicting disease progression and guiding treatment selection to minimize adverse effects. In chemotherapy-induced peripheral neuropathy (CIPN), studies have identified novel loci associated with taxane-induced neuropathy, with logistic regression models adjusting for age and treatment arm used to calculate odds ratios for severe (≥grade 3) neuropathies.^[3] Furthermore, a genome-wide meta-analysis validated a role for S1PR1in microtubule targeting agent-induced sensory peripheral neuropathy, suggesting potential targets for intervention or risk assessment.^[7]The field of pharmacogenomics is increasingly vital, informing the management of CIPN by identifying genetic predictors of neuropathy from various chemotherapeutic agents, including paclitaxel, carboplatin, oxaliplatin, and cisplatin.^[39]Such genetic insights enable clinicians to tailor chemotherapy regimens, select alternative agents, or implement prophylactic measures for patients identified to be at high genetic risk of severe neuropathy, thereby improving treatment tolerability and patient outcomes.

Comorbidities and Disease Complexity

Acquired peripheral neuropathy frequently coexists with or arises as a complication of other chronic conditions, necessitating a holistic approach to patient care. Diabetic peripheral neuropathy (DPN), for example, is a significant complication of type 2 diabetes, contributing to substantial healthcare costs and impacting patient quality of life.^[40]DPN is also a major risk factor for diabetic foot ulcers (DFU), a severe complication that can lead to amputations.^[41] Research has identified genetic associations, such as MAPK14with diabetic foot ulcers, highlighting genetic links between diabetes complications.^[25]Moreover, peripheral artery disease (PAD) is genetically and causally linked to type 2 diabetes, further complicating the clinical picture of neuropathy in diabetic patients.^[42]Understanding these complex interrelationships and genetic predispositions is crucial for comprehensive management, allowing for earlier screening for related conditions and integrated care plans to address the multifaceted challenges faced by patients with acquired peripheral neuropathy and its comorbidities.

Frequently Asked Questions About Acquired Peripheral Neuropathy

These questions address the most important and specific aspects of acquired peripheral neuropathy based on current genetic research.

---

1. Why did my chemotherapy cause severe neuropathy, but my friend’s didn’t?

Your genetic makeup plays a significant role in how your body responds to chemotherapy. Variants in genes like VAC14, NXN, or GPR68 can influence how your nerves process and react to these drugs, making you more susceptible to nerve damage compared to someone else. This can affect drug metabolism or nerve repair.

2. I have diabetes, why do my feet hurt so much more than others with diabetes?

Even with similar diabetes management, your genetic background can influence your risk and severity of diabetic peripheral neuropathy. For instance, specific genetic loci, like one on chromosome 2q24, can affect genes such asSCN2Aexpression, making you more prone to nerve damage and pain.

3. My mom had neuropathy after her illness; am I more likely to get it too?

While acquired neuropathy isn’t inherited directly, your family’s genetics can increase your susceptibility to developing it. Genetic factors influence how your body responds to various triggers like infections or metabolic disorders, which means you might have a higher predisposition to nerve damage.

4. Why do my neuropathy symptoms feel so much worse than my doctor expected?

Genetic factors can significantly influence the severity and progression of your neuropathy. Your unique genetic predispositions can affect your nerve repair mechanisms or immune responses, leading to more pronounced symptoms than typically observed in others with similar conditions.

5. Is there a way to know if I’m at higher risk before starting certain treatments?

Yes, understanding your genetic profile can help identify your risk. Researchers are identifying specific genetic variants, such as polymorphisms in IL2RA, ZNF648, or RSP04, that can predict an increased likelihood of neuropathy from certain medications. This can lead to personalized risk stratification.

6. Why don’t the usual treatments seem to help my neuropathy much?

Your genetic makeup can influence how effectively your body responds to treatments. Genetic predispositions can affect nerve repair mechanisms, drug metabolism, or immune responses, which might mean that standard therapies are less effective for your specific genetic profile.

7. Will my nerve damage ever truly heal, or will it just get worse?

The ability of your nerves to repair themselves can be influenced by your genes. While some nerve damage can improve, genetic predispositions can affect your body’s natural nerve repair mechanisms, impacting the extent of recovery or potential for progression.

8. My hands and feet tingle sometimes; should I be worried about neuropathy?

Tingling in your hands and feet, known as paresthesia, is a common early symptom of peripheral neuropathy. While various factors can cause it, genetic predispositions can increase your susceptibility, influencing whether you develop these symptoms and their severity.

9. Could my daily habits or choices affect my neuropathy risk?

Yes, your lifestyle choices, especially those affecting metabolic health, can interact with your genetic predispositions. For example, managing conditions like diabetes, which has genetic links to neuropathy risk, through diet and exercise can influence the development and progression of your neuropathy.

10. Could a DNA test tell me if I’m prone to getting neuropathy?

Yes, genetic testing is increasingly being used to identify predispositions. Specific genetic variants associated with increased risk for different types of acquired neuropathy, like those linked to chemotherapy or diabetes, can be identified, helping to assess your individual risk.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Khan, Z, et al. “Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.”Genome Med, 2023.

[2] Leger, P. D. Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.J Neurovirol, vol. 20, no. 2, 2014, pp. 166-71.

[3] Sucheston-Campbell LE, et al. “Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.”Pharmacogenet Genomics, vol. 28, no. 2, 2018, pp. 39–48.

[4] Hertz DL, et al. “Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.”Clin Cancer Res, vol. 22, no. 18, 2016, pp. 4686–4695.

[5] Tang Y, et al. “A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies.”Diabetes, vol. 68, no. 8, 2019, pp. 1656–1668.

[6] Ishigaki, K, et al. “Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases.” Nat Genet, 2020.

[7] Chua KC, et al. “Genome-Wide Meta-Analysis Validates a Roless for S1PR1in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.”Clin Pharmacol Ther, vol. 108, no. 6, 2020, pp. 1272-1282.

[8] Tao, F, et al. “Modifier Gene Candidates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study.”J Neuromuscul Dis, 2019.

[9] Guindo-Martinez, M, et al. “The impact of non-additive genetic associations on age-related complex diseases.” Nat Commun, 2021.

[10] Sofer, T, et al. “Variants Associated with the Ankle Brachial Index Differ by Hispanic/Latino Ethnic Group: a genome-wide association study in the Hispanic Community Health Study/Study of Latinos.”Sci Rep, 2019.

[11] Ward-Caviness, C. K., et al. Genetic Variants in the Bone Morphogenic Protein Gene Family Modify the Association between Residential Exposure to Traffic and Peripheral Arterial Disease.PLoS One, vol. 11, no. 4, 2016, p. e0153215.

[12] Maier, L. M., et al. “IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.”PLoS Genet, vol. 5, no. 1, 2009, e1000322.

[13] Park SB, et al. “Chemotherapy-induced peripheral neurotoxicity: A critical analysis.” CA Cancer J. Clin., vol. 63, no. 6, 2013, pp. 419–437.

[14] Diouf B, Crews KR, Pei D, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA. 2015;313:815–823.

[15] Nyrop KA, et al. “Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.”Cancer, vol. 125, no. 17, 2019, pp. 2945–2954.

[16] Liu TY, et al. “Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.”Sci Adv, vol. 10, no. 20, 2024, pp. eadn7302.

[17] Hershman DL, et al. “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline.”J. Clin. Oncol., vol. 32, no. 18, 2014, pp. 1941–1967.

[18] Kullo, I. J. The ATXN2-SH2B3locus is associated with peripheral arterial disease: an electronic medical record-based genome-wide association study.Front Genet, vol. 5, 2014, p. 166.

[19] Argyriou AA, Bruna J, Genazzani AA, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. Nat Rev Neurol. 2017;13:492–504.

[20] Chang, X., et al. “Protective activity of salidroside against ethanol-induced gastric ulcer via theMAPK/NF-κB pathway in vivo and in vitro.” International Immunopharmacology, vol. 28, no. 2, 2015, pp. 604-15.

[21] Persson, A.-K., et al. “Sodium channels, mitochondria, and axonal degeneration in peripheral neuropathy.”Trends in Molecular Medicine, vol. 22, no. 5, 2016, pp. 377-90.

[22] Huang, C.-W., et al. “Nociceptors of dorsal root ganglion express proton-sensing G-protein-coupled receptors.” Molecular and Cellular Neuroscience, vol. 36, no. 2, 2007, pp. 195-210.

[23] Latorraca, N. R., et al. “How GPCR phosphorylation patterns orchestrate arrestin-mediated signaling.” Cell, vol. 183, no. 7, 2020, pp. 1813-25.e18.

[24] Quarta, S., et al. “Sphingosine-1-phosphate and theS1P3 receptor initiate neuronal retraction via RhoA/ROCK associated with CRMP2 phosphorylation.” Frontiers in Molecular Neuroscience, vol. 10, 2017, p. 13.

[25] Meng W, Agius R, Smith R, et al. A genome-wide association study suggests that MAPK14 is associated with diabetic foot ulcers. Br J Dermatol. 2017;177:164–173.

[26] Jordanova, Albena, et al. “Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease.”Brain, vol. 126, no. 3, 2003, pp. 590–597.

[27] Jager, S. E., et al. “Changes in the transcriptional fingerprint of satellite glial cells following peripheral nerve injury.” Glia, vol. 68, no. 7, 2020, pp. 1375-95.

[28] Cheng, K. I., et al. “Persistent mechanical allodynia positively correlates with an increase in activated microglia and increased P-p38 mitogen-activated protein kinase activation in streptozotocin-induced diabetic rats.” European Journal of Pain, vol. 18, no. 2, 2014, pp. 162-73.

[29] Chong, J. A., et al. “REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons.”Cell, vol. 90, no. 5, 1997, pp. 825-30.

[30] Lewis, W., et al. “Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.”Laboratory Investigation, vol. 81, no. 6, 2001, pp. 777-90.

[31] Stockstill, K., et al. “Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain.”Journal of Experimental Medicine, vol. 215, no. 5, 2018, pp. 1301-13.

[32] Lenk, G. M., and M. H. Meisler. “Mouse models of PI(3,5)P2 deficiency with impaired lysosome function.” Methods in Enzymology, vol. 534, 2014, pp. 245-60.

[33] Prokop, A. “The intricate relationship between microtubules and their associated motor proteins during axon growth and maintenance.” Neural Development, vol. 8, no. 1, 2013, p. 17.

[34] Klebe, S., et al. “KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations.” European Journal of Human Genetics, vol. 20, no. 6, 2012, pp. 645-49.

[35] Delague, V., et al. “Mutations in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal recessive Charcot-Marie-Tooth type 4H.” American Journal of Human Genetics, vol. 81, no. 1, 2007, pp. 1-16.

[36] Lam, S. W., et al. “Genotypes of CYP2C8 and FGD4and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.”British Journal of Cancer, vol. 115, no. 11, 2016, pp. 1335-42.

[37] Rinn, J. L., and H. Y. Chang. “Genome regulation by long noncoding RNAs.” Annual Review of Biochemistry, vol. 81, 2012, pp. 145-66.

[38] Kaluza, D., et al. “Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 12, 2013, pp. 2851-60.

[39] Adjei AA, Lopez CL, Schaid DJ, et al. Genetic predictors of chemotherapy-induced peripheral neuropathy from paclitaxel, carboplatin and oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB study. Cancers. 2021;13:1084.

[40] American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.

[41] Tresierra-Ayala M, Rojas AG. Association between peripheral arterial disease and diabetic foot ulcers in patients with diabetes mellitus type 2. Medicina Universitaria. 2017;19(76):123–126.

[42] Xiu X, Liu Y, Li C, et al. Genetic evidence for a causal relationship between type 2 diabetes and peripheral artery disease in both Europeans and East Asians. BMC Med. 2022;20:308.